Shares of Merck & Co. (MRK) experienced a premarket drop of 1.6% following the release of its 2026 guidance. While the pharmaceutical giant's fourth-quarter results met earnings forecasts, with a $2.04 per share, and slightly exceeded revenue estimates, the future outlook is what spooked investors. The market is clearly focused on long-term performance.